Sunday - November 15, 2026
Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review
October 26, 2026
LEVERKUSEN, Germany, Oct. 26 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:

* * *

Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review

*

Berlin, October 26, 2026 - Bayer announced today that China's National Medical Products Administration (NMPA) has granted marketing authorization for asundexian, under the bran . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products